• Please log in or register to access this feature.

OFFICIAL COMMUNICATIONS OF THE SSC

You have free access to this content

Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis

  1. M. CARRIER1,
  2. A. A. KHORANA2,
  3. J. I. ZWICKER3,
  4. G. H. LYMAN4,
  5. G. LE GAL5,
  6. A. Y. Y. LEE6,
  7. on behalf of the subcommittee on Haemostasis and Malignancy for the SSC of the ISTH

Article first published online: 12 DEC 2012

DOI: 10.1111/jth.12028

Issue

Journal of Thrombosis and Haemostasis

Journal of Thrombosis and Haemostasis

Volume 10, Issue 12, pages 2599–2601, December 2012

Additional Information

How to Cite

CARRIER, M., KHORANA, A. A., ZWICKER, J. I., LYMAN, G. H., LE GAL, G., LEE, A. Y. Y. and on behalf of the subcommittee on Haemostasis and Malignancy for the SSC of the ISTH (2012), Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. Journal of Thrombosis and Haemostasis, 10: 2599–2601. doi: 10.1111/jth.12028

Author Information

  1. 1

    Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada

  2. 2

    Division of Hematology and Oncology, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY

  3. 3

    Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

  4. 4

    Duke University and the Duke Cancer Institute, Durham, NC, USA

  5. 5

    Department of Internal Medicine and Chest Diseases, EA3878, Brest University Hospital, Brest, France

  6. 6

    Thrombosis Program, Division of Hematology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

*Agnes Y. Lee, Division of Hematology, Diamond Health Care Center, University of British Columbia, 2775 Laurel Street 10th floor, Vancouver, BC V5Z 1M9, Canada. Tel.: 604 875 4952; fax: 604 875 4696. E-mail: alee14@bccancer.bc.ca

Publication History

  1. Issue published online: 12 DEC 2012
  2. Article first published online: 12 DEC 2012
  3. Accepted manuscript online: 18 OCT 2012 11:37AM EST
  4. Received 16 July 2012, accepted 30 September 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (75K)

References

  • 1
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632–4.
    Direct Link:
  • 2
    Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715–22.
  • 3
    Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Bennett C, Langensiepen S, Hyde C, Engert A. Erythropoietin or Darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006; Issue 3: Art. No.: CD003407.
  • 4
    Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277–85.
  • 5
    Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blade J, Kyle R, Westin J, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414–23.
  • 6
    Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011; 9: 653–63.
    Direct Link:
  • 7
    Mandalà M, Barni S, Floriani I, Isa L, Fornarini G, Marangolo M, Mosconi S, Corsi D, Rulli E, Frontini L, Cortesi E, Zaniboni A, Aglietta M, Labianca R. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the ‘GISCAD-alternating schedule’ study findings. Eur J Cancer 2009; 45: 65–73.
  • 8
    Kucher N. Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med 2011; 364: 861–9.
  • 9
    Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD, Kearon C, Schunemann HJ, Crowther M, Pauker SG, Makdissi R, Guyatt GACoCP. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141(Suppl. 2): e351S–418S.
  • 10
    The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990; 263: 2753–9.
  • 11
    van Belle A, Buller HR, Huisman MV, Huisman PM, Kaasjager K, Kamphuisen PW, Kramer MH, Kruip MJ, Kwakkel-van Erp JM, Leebeek FW, Nijkeuter M, Prins MH, Sohne M, Tick LW. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 2006; 295: 172–9.
  • 12
    Campigotto F, Neuberg D, Zwicker JI. Biased estimation of thrombosis rates in cancer studies using the method of kaplan and meier. J Thromb Haemost 2012; 10: 1449–51.
    Direct Link:
  • 13
    Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007; 13: 559–65.
  • 14
    Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141–54.
View Full Article with Supporting Information (HTML) Get PDF (75K)